55 related articles for article (PubMed ID: 19815051)
1. The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells.
Grozinsky-Glasberg S; Rubinfeld H; Nordenberg Y; Gorshtein A; Praiss M; Kendler E; Feinmesser R; Grossman AB; Shimon I
Mol Cell Endocrinol; 2010 Feb; 315(1-2):87-94. PubMed ID: 19815051
[TBL] [Abstract][Full Text] [Related]
2. 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells.
Hung JY; Hsu YL; Li CT; Ko YC; Ni WC; Huang MS; Kuo PL
J Agric Food Chem; 2009 Oct; 57(20):9809-16. PubMed ID: 19799425
[TBL] [Abstract][Full Text] [Related]
3. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer.
Nagaraja AK; Creighton CJ; Yu Z; Zhu H; Gunaratne PH; Reid JG; Olokpa E; Itamochi H; Ueno NT; Hawkins SM; Anderson ML; Matzuk MM
Mol Endocrinol; 2010 Feb; 24(2):447-63. PubMed ID: 20081105
[TBL] [Abstract][Full Text] [Related]
4. Detection and significance of AKT/mTOR/P70S6K signaling pathway in gastrointestinal stromal tumors.
Wang M; Zhong XG
Asian J Surg; 2023 Dec; 46(12):5707-5708. PubMed ID: 37625962
[No Abstract] [Full Text] [Related]
5. Everolimus Acts in Synergy with Vinorelbine to Suppress the Growth of Hepatocellular Carcinoma.
Huynh H; Ng WH; Soo KC
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203186
[TBL] [Abstract][Full Text] [Related]
6. A Stable Micellar Formulation of RAD001 for Intracerebroventricular Delivery and the Treatment of Alzheimer's Disease and Other Neurological Disorders.
Gianessi L; Magini A; Dominici R; Giovagnoli S; Dolcetta D
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139306
[TBL] [Abstract][Full Text] [Related]
7. Combining MTI-31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy.
Zhang W; Yang C; Zou L; Zang Y; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
J Appl Genet; 2024 Feb; 65(1):103-112. PubMed ID: 37932653
[TBL] [Abstract][Full Text] [Related]
8. Correction to: Combining MTI‑31 with RAD001 inhibits tumor growth and invasion of kidney cancer by activating autophagy.
Zhang W; Yang C; Zou L; Zang Y; Hu J; Hu Y; Xu C; Liu R; Wang H; Xiong Z
J Appl Genet; 2024 Feb; 65(1):223. PubMed ID: 37968428
[No Abstract] [Full Text] [Related]
9. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes.
Lim SM; Chang H; Yoon MJ; Hong YK; Kim H; Chung WY; Park CS; Nam KH; Kang SW; Kim MK; Kim SB; Lee SH; Kim HG; Na II; Kim YS; Choi MY; Kim JG; Park KU; Yun HJ; Kim JH; Cho BC
Ann Oncol; 2013 Dec; 24(12):3089-94. PubMed ID: 24050953
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity of everolimus and 5-aza-2'-deoxycytidine in medullary thyroid carcinoma cell lines.
Vitale G; Dicitore A; Pepe D; Gentilini D; Grassi ES; Borghi MO; Gelmini G; Cantone MC; Gaudenzi G; Misso G; Di Blasio AM; Hofland LJ; Caraglia M; Persani L
Mol Oncol; 2017 Aug; 11(8):1007-1022. PubMed ID: 28453190
[TBL] [Abstract][Full Text] [Related]
11. Igf-I influences everolimus activity in medullary thyroid carcinoma.
Gentilin E; Di Pasquale C; Rossi M; Tagliati F; Gagliano T; Rossi R; Pelizzo M; Merante Boschin I; Degli Uberti EC; Zatelli MC
Front Endocrinol (Lausanne); 2015; 6():63. PubMed ID: 25999915
[TBL] [Abstract][Full Text] [Related]
12. Preliminary report of the use of everolimus in a patient with progressive medullary thyroid carcinoma.
Druce M; Chung TT; Grozinsky-Glasberg S; Gross DJ; Grossman AB
Clin Endocrinol (Oxf); 2012 Jul; 77(1):154-5. PubMed ID: 22103914
[No Abstract] [Full Text] [Related]
13. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
Faggiano A; Ramundo V; Dicitore A; Castiglioni S; Borghi MO; Severino R; Ferolla P; Crinò L; Abbruzzese A; Sperlongano P; Caraglia M; Ferone D; Hofland L; Colao A; Vitale G
J Cell Mol Med; 2012 Jul; 16(7):1563-72. PubMed ID: 21883896
[TBL] [Abstract][Full Text] [Related]
14. Metastatic medullary thyroid carcinoma: a new way forward.
Angelousi A; Hayes AR; Chatzellis E; Kaltsas GA; Grossman AB
Endocr Relat Cancer; 2022 May; 29(7):R85-R103. PubMed ID: 35521769
[TBL] [Abstract][Full Text] [Related]
15. Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A; Gambale C; Prete A; Elisei R
Front Endocrinol (Lausanne); 2022; 13():864253. PubMed ID: 35422765
[TBL] [Abstract][Full Text] [Related]
16. The antiproliferative effect of pasireotide LAR alone and in combination with everolimus in patients with medullary thyroid cancer: a single-center, open-label, phase II, proof-of-concept study.
Faggiano A; Modica R; Severino R; Camera L; Fonti R; Del Prete M; Chiofalo MG; Aria M; Ferolla P; Vitale G; Pezzullo L; Colao A
Endocrine; 2018 Oct; 62(1):46-56. PubMed ID: 29572709
[TBL] [Abstract][Full Text] [Related]
17. Molecular markers of paragangliomas/pheochromocytomas.
Zhikrivetskaya SO; Snezhkina AV; Zaretsky AR; Alekseev BY; Pokrovsky AV; Golovyuk AL; Melnikova NV; Stepanov OA; Kalinin DV; Moskalev AA; Krasnov GS; Dmitriev AA; Kudryavtseva AV
Oncotarget; 2017 Apr; 8(15):25756-25782. PubMed ID: 28187001
[TBL] [Abstract][Full Text] [Related]
18. Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.
Schneider TC; de Wit D; Links TP; van Erp NP; van der Hoeven JJ; Gelderblom H; van Wezel T; van Eijk R; Morreau H; Guchelaar HJ; Kapiteijn E
Int J Endocrinol; 2015; 2015():348124. PubMed ID: 26294908
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
